Provided by Tiger Trade Technology Pte. Ltd.

Agilent

153.56
-0.2800-0.18%
Post-market: 153.560.00000.00%19:41 EDT
Volume:2.77M
Turnover:424.07M
Market Cap:43.47B
PE:30.28
High:154.03
Open:152.68
Low:151.64
Close:153.84
52wk High:163.75
52wk Low:108.35
Shares:283.05M
Float Shares:281.64M
Volume Ratio:0.88
T/O Rate:0.98%
Dividend:1.01
Dividend Rate:0.66%
EPS(TTM):5.07
EPS(LYR):4.59
ROE:20.97%
ROA:8.72%
PB:5.90
PE(LYR):33.47

Loading ...

Agilent files Form 3 for VP, Chief Accounting Officer Timothy Charles Downs

Reuters
·
Jun 06

A Look At Agilent Technologies (A) Valuation As FDA Approval AI Deal And Earnings Update Draw Focus

Simply Wall St.
·
Jun 05

Revvity Inc. Stock Underperforms Thursday When Compared To Competitors Despite Daily Gains

Dow Jones
·
Jun 05

Agilent Technologies Inc. Stock Outperforms Competitors On Strong Trading Day

Dow Jones
·
Jun 04

Agilent Technologies Partners With OpenAI, Boston Consulting for AI Deployment

MT Newswires Live
·
Jun 03

Agilent teams with OpenAI, BCG to scale AI across products and operations

Reuters
·
Jun 03

Agilent, OpenAI, Bcg Collaborate to Accelerate Customer-Focused, AI-Driven Scientific Innovation

THOMSON REUTERS
·
Jun 03

Agilent price target lowered to $165 from $180 at HSBC

TIPRANKS
·
Jun 03

U.S. RESEARCH ROUNDUP-Aveanna Healthcare, Palo Alto, Ulta Beauty

Reuters
·
Jun 03

Agilent receives FDA approval for expanded use of PD-L1 IHC 22C3 pharmDx

TIPRANKS
·
Jun 03

Agilent Technologies' Cancer Test Gets Expanded Approval From FDA

Dow Jones
·
Jun 03

Agilent wins FDA nod to expand PD-L1 22C3 test use on Dako Omnis platform

Reuters
·
Jun 03

Agilent Receives FDA Approval for Expanded Use of Pd-L1 Ihc 22C3 Pharmdx on Dako Omnis in Esophageal Squamous Cell Carcinoma, Triple-Negative Breast Cancer, Cervical Cancer, and Gastric or Gastroesophageal Junction Adenocarcinoma

THOMSON REUTERS
·
Jun 03

Agilent director Mikael Dolsten sells 1,600 common shares for $216,672

Reuters
·
Jun 03

Agilent Is Maintained at Buy by B of A Securities

Dow Jones
·
Jun 03

BofA Securities Adjusts Agilent Technologies PT to $155 From $145

MT Newswires Live
·
Jun 02

Triller Group Inc. Receives Nasdaq Exception To Regain Minimum Bid Price Compliance

GlobeNewswire
·
Jun 02

Lantheus' LNTH-2513 (18F-GP1) PET/CT Awarded SNMMI’s Image of the Year

GlobeNewswire
·
Jun 02

Wall Street Analysts Are Bullish on Top Healthcare Picks

TIPRANKS
·
Jun 02

Agilent price target raised to $155 from $145 at BofA

TIPRANKS
·
Jun 02